文献速递疝与腹壁外科

Hugo机器人辅助系统用于腹股沟疝与腹壁疝修补的前瞻性单臂临床试验

Inguinal and Ventral Hernia Repair with the Hugo Robotic-Assisted Surgery System: A Prospective, Single-arm, Clinical Trial.
PubMed 文献 · Ann Surg · 2026-05-11

该研究为FDA批准的前瞻性多中心单臂器械豁免试验,纳入206例适合微创修补的无并发症、非急诊、非复发腹股沟疝或腹壁疝成人患者,实际193例在7个中心完成手术。主要终点为手术成功率(无中转)和术后30天内手术/器械相关手术部位事件率。结果显示手术成功率为100%(193/193),腹股沟疝队列SSE率为0%(0/97),腹壁疝队列为2.1%(2/96)。结论认为Hugo RAS系统在美国人群中用于腹股沟疝和腹壁疝修补安全有效。

要点

  • Hugo机器人系统在腹股沟疝和腹壁疝修补中手术成功率达100%,无中转。
  • 术后30天手术部位事件率腹股沟疝为0%,腹壁疝为2.1%。
  • 研究为单臂设计,纳入无并发症、非急诊、非复发疝的成人患者。

核心结论

  • Hugo机器人辅助手术系统在美国患者群体中用于腹股沟疝和腹壁疝修补安全有效。

研究设计与样本

  • 前瞻性、多中心、单臂、FDA批准的研究性器械豁免试验,纳入7个中心的成人患者206例,实际手术193例,历时11个月。

主要发现

  • 平均年龄57.4岁(标准差13.6),平均BMI 28.4 kg/m2(标准差4.8),男性占78.8%(152/193)。
  • 腹股沟疝队列97例,腹壁疝队列96例。
  • 手术成功率为100%(193/193),无中转。
  • 腹股沟疝队列手术部位事件率为0%(0/97),腹壁疝队列为2.1%(2/96)。

关键数值与推荐

  • 主要有效性终点为手术成功率,即未从Hugo RAS系统中转至其他入路。
  • 主要安全性终点为术后30天内发生一项或以上手术和/或器械相关手术部位事件的患者比例。

临床怎么用

  • 对于适合微创修补的无并发症、非急诊、非复发腹股沟疝或腹壁疝成人患者,Hugo RAS系统可作为机器人辅助修补的选择之一。

局限性

  • 研究为单臂设计,无对照组。
  • 仅纳入无并发症、非急诊、非复发疝患者,结论外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the safety and efficacy of the Hugo robotic-assisted surgery (RAS) platform in the repair of inguinal and ventral hernias. SUMMARY BACKGROUND DATA: Robotic-assisted surgery has increasingly been utilized in inguinal and ventral hernia repair. Here, we share the results of the first trial of the Hugo RAS platform for use in inguinal and ventral hernia repair in the US. METHODS: This was a prospective, multi-center, single-arm, FDA-approved, investigational device exemption study. Adult patients (N=206) eligible for minimally invasive repair of uncomplicated, non-emergent, and non-recurrent inguinal or ventral hernias were enrolled across 7 sites. Surgeries were performed on 193 patients over 11 months. The primary effectiveness and safety endpoints were the rate of surgical success, defined as the procedure not being converted from the use of the Hugo RAS system to another approach, and the rate of patients with one or more procedure- and/or device-related surgical-site events (SSEs) through 30 days post-procedure, respectively. RESULTS: The mean (standard deviation) age and body-mass index were 57.4 (13.6) years and 28.4 (4.8) kg/m2, respectively, and 78.8% (152/193) of patients were male. There were 97 patients treated in the inguinal hernia cohort and 96 treated in the ventral hernia cohort. The surgical success rate was 100% (193/193), with no conversions, and the SSE rates for the inguinal and ventral cohorts were 0% (0/97) and 2.1% (2/96), respectively. CONCLUSIONS: The Hugo RAS system was found to be safe and effective in the repair of inguinal and ventral hernias in a US patient population.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Greenberg JA, Malcher F, Panchal A, et al. Inguinal and Ventral Hernia Repair with the Hugo Robotic-Assisted Surgery System: A Prospective, Single-arm, Clinical Trial. Ann Surg. 2026. PMID: 42108492. doi:10.1097/SLA.0000000000007084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。